Quantitative Contribution of Clinical Attacks to Residual Disability in Patients With AQP4-Antibody Neuromyelitis Optica Spectrum Disorder.
Chen B. et al, (2025), Neurology, 104
Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM) Associated with GlyR Antibody in an APECED Patient.
Ochoa S. et al, (2024), J Clin Immunol, 45
The influence of MOGAD on diagnosis of multiple sclerosis using MRI
Geraldes R. et al, (2024), Nature Reviews Neurology
Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders.
Oertel FC. et al, (2024), Neurol Neuroimmunol Neuroinflamm, 11
Study of seasonality of attacks in MOG antibody-associated disease.
Francis A. et al, (2024), Mult Scler Relat Disord, 90
Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis.
Arnett S. et al, (2024), J Neurol
Characterizing mortality in patients with AQP4-Ab+ neuromyelitis optica spectrum disorder.
Francis A. et al, (2024), Ann Clin Transl Neurol
MOG-IgA as a Potential Marker of Germinal Center Activity.
Handel AE. et al, (2024), JAMA Neurol, 81
Usability of the zilucoplan prefilled syringe for the treatment of generalized myasthenia gravis: insights from a human factors validation study
Domanska B. et al, (2024), Expert Review of Medical Devices
Do Early Relapses Predict the Risk of Long-Term Relapsing Disease in an Adult and Paediatric Cohort with MOGAD?
Chen B. et al, (2023), Ann Neurol, 94, 508 - 517
The effect of smoking on MRI lesion resolution in NMOSD-AQP4 and MOGAD.
Berhanu D. et al, (2023), Mult Scler, 29, 1250 - 1256
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.
Paul F. et al, (2023), Neurol Neuroimmunol Neuroinflamm, 10
A systematic literature review to examine the considerations around pregnancy in women of child-bearing age with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) or aquaporin 4 neuromyelitis optica spectrum disorder (AQP4+ NMOSD).
Leite MI. et al, (2023), Mult Scler Relat Disord, 75
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
Howard JF. et al, (2023), The Lancet Neurology, 22, 395 - 406
Diagnostic value of intereye difference metrics for optic neuritis in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders.
Oertel FC. et al, (2023), J Neurol Neurosurg Psychiatry
Shared imaging markers of fatigue across multiple sclerosis, aquaporin-4 antibody neuromyelitis optica spectrum disorder and MOG antibody disease.
Camera V. et al, (2023), Brain Commun, 5
The Acute Optic Neuritis Network (ACON): Study protocol of a non-interventional prospective multicenter study on diagnosis and treatment of acute optic neuritis.
Asseyer S. et al, (2023), Front Neurol, 14